Morgan Stanley initiated coverage on Vir Biotechnology with a new price target
$VIR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Morgan Stanley initiated coverage of Vir Biotechnology with a rating of Underweight and set a new price target of $15.00